Vitality Biopharma Receives $8.5 Million Common Stock Financing

Financing to support company at least into 2020 and for the initiation of multiple Phase 2 clinical trials LOS ANGELES, CA – (October 23, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Vitality Biopharma Announces Neural Repair Treatment Patent Filings

Focused on remyelination, a form of neural repair that may benefit multiple sclerosis as well as addiction, stroke, and schizophrenia LOS ANGELES, CA – (October 3, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Vitality Biopharma Scientific Co-Founder to Present Recent Data at CannMed Medical Conference in Los Angeles

Dr. Brandon Zipp to discuss outlook for Vitality’s VBX-100 THC prodrug in scientific presentation held at UCLA LOS ANGELES, CA – (September 13, 2018) – Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment...

Vitality Biopharma THC Prodrug VBX-100 Demonstrates Positive Safety Results

During safety pharmacology screening Vitality’s THC prodrug demonstrates no signs of adverse or off-target effects LOS ANGELES, CA – August 21, 2018 – Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious...

Vitality Biopharma Receives DEA Renewal for Cannabinoid Pharma Development Program

Approval of Vitality research program and manufacturing operations through May 2019 LOS ANGELES, June 20, 2018 — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it...

Vitality Biopharma Sponsors Clinical Research Forum on Ending Opioid Epidemic

Lack of effective response drives Los Angeles meeting to discuss immediate reduction of opiate painkillers LOS ANGELES, June 05, 2018 — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids as an alternative to opiate abuse, today announced its sponsorship and...

Vitality Biopharma to Present at the 8th Annual LD Micro Invitational

LOS ANGELES, May 30, 2018 — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Wednesday, June 6th at 11...

Vitality Biopharma Discovers and Patents Use of Cannabinoids for C.diff-Associated Diarrhea and Colitis

Vitality’s GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent difficile infections LOS ANGELES, CA – (May 10, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and...

Vitality Biopharma Launches Canadian Subsidiary Focused on Cannabinoid Genetics R&D

Wholly-owned subsidiary to enable access to best available cannabinoid compounds in a federally-compliant manner and facilitate key collaborative research programs LOS ANGELES, CA – (April 5, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Vitality Biopharma Files Intellectual Property in All Major Pharmaceutical Markets Worldwide

THC prodrugs including VBX-100 designed to deliver cannabinoids for targeted therapeutic effects without psychoactivity LOS ANGELES, CA – (March 28, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and...